The Innovative Health Initiative (IHI) - a European Union (EU) public-private partnership funding health research and innovation - has boasted that it has made a major step forward for animal welfare.
This relates to the tests that must be run by manufacturers before a new batch of medicines can be released for use to check that it is safe for patients, whether human or animal.
The tests required to assess the safety and quality of different types of medicines are set out in a reference work called the European Pharmacopoeia. For medicines administered by injection, such as vaccines, some antibiotics, and blood products, manufacturers have to test for pyrogens, contaminants which can trigger a fever.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze